Indication
Human Immunodeficiency Virus (HIV)-1 Infection
1 clinical trial
3 products
Product
ElvucitabineClinical trial
An Open-Label, 48-Week Extension Study of Elvucitabine Administered In Combination With Background Antiretroviral Agents in Participants Who Have Completed 14 Days of Treatment in Protocol ACH443-014A.Status: Completed, Estimated PCD: 2008-12-01
Product
EmtricitabineProduct
Lamivudine